MSD Looks Ahead For Japan Growth Amid Policy Challenges
This article was originally published in PharmAsia News
Despite a stream of new launches over the past few years, last year was a “challenging” one for MSD in Japan due mainly to generic competition, but the company expects the new products to help drive growth over the next few years.
You may also be interested in...
A group of plaintiffs and their lawyers have now confirmed they will bring legal action in Japan later this month seeking damages against the country’s government and two multinational manufacturers of HPV vaccines over claims the products caused a variety of health problems.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.